Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial

Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB). We have evaluated the immunotherapeutic potential of Mycobacterium indicus...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Surendra K., Katoch, Kiran, Sarin, Rohit, Balambal, Raman, Kumar Jain, Nirmal, Patel, Naresh, Murthy, Kolluri J. R., Singla, Neeta, Saha, P. K., Khanna, Ashwani, Singh, Urvashi, Kumar, Sanjiv, Sengupta, A., Banavaliker, J. N., Chauhan, D. S., Sachan, Shailendra, Wasim, Mohammad, Tripathi, Sanjay, Dutt, Nilesh, Jain, Nitin, Joshi, Nalin, Penmesta, Sita Ram Raju, Gaddam, Sumanlatha, Gupta, Sanjay, Khamar, Bakulesh, Dey, Bindu, Mitra, Dipendra K., Arora, Sunil K., Bhaskar, Sangeeta, Rani, Rajni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469738/
https://www.ncbi.nlm.nih.gov/pubmed/28611374
http://dx.doi.org/10.1038/s41598-017-03514-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469738/
https://www.ncbi.nlm.nih.gov/pubmed/28611374
http://dx.doi.org/10.1038/s41598-017-03514-1

Ejemplares similares